Oslo, Norway, 14 June 2021 - Targovax ASA (OSE: TRVX), a clinical-stage immuno
-oncology company developing immune activators to target hard-to-treat solid
tumors, has released two video presentations related to the ONCOS-102
mesothelioma 24-month data.

The 24-month follow-up data from the randomized phase 1/2 trial of ONCOS-102 in
combination with Standard of Care (SoC) chemotherapy in patients with malignant
pleural mesothelioma (MPM) was announced 10 June 2021 (see press release
here (https://www.targovax.com/en/targovaxs-oncos-102-mesothelioma-24-month-data
-shows-class-leading-median-overall-survival/)). It showed that the median
overall survival will be in the range of 21.9 to 25.0 months for first-line
ONCOS-102-treated patients in the randomized group (n=8). This is a clear
improvement over the median overall survival of 13.5 months observed in the
first-line standard of care-only control group (n=6). Previous malignant pleural
mesothelioma clinical trials have reported median overall survival in the range
of 12-16 months for patients receiving the same SoC chemotherapy treatment[1].

In addition, a broad and powerful immune activation pattern was observed in
patients treated with ONCOS-102, clearly associated with both tumor responses
and survival outcomes.

For the presentations of the data, please see link below:

  · Video presentations related to the ONCOS-102 mesothelioma 24-month
data (https://www.targovax.com/en/mesothelioma-24-month-data/)


1 Vogelzang 2003, Ceresoli 2006, Zalcman 2015, Tsao 2019, Scagliotti 2019, Baas
2020

For further information, please contact:
Øystein Soug, CEO
Phone: +47 906 56 525
Email: oystein.soug@targovax.com

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

IR enquires:
Kim Sutton Golodetz - LHA Investor Relations (US)
Email: kgolodetz@lhai.com
Phone: +1 212-838-3777

About Targovax

Activating the patient's immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
immune activators to target hard-to-treat solid tumors. Targovax aims to unlock
greater clinical benefits in cancer patients by deploying multifunctional
platforms to target key immune regulators and oncogenic drivers. Targovax's
focus is to "activate the patient's immune system to fight cancer", thus
extending and transforming the lives of cancer patients. Targovax's pipeline
aims at different cancer indications, including melanoma, mesothelioma and
colorectal cancer. The products are designed to harness the patient's own immune
system to fight the cancer, whilst also delivering a favorable safety and
tolerability profile.

Targovax's lead clinical candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect cancer
cells and activate the immune system to fight the cancer. On the back of very
encouraging data in several indications, in monotherapy and in multiple
combination, the next development steps for ONCOS-102 will involve a clinical
trial with registration intent in checkpoint inhibitor refractory melanoma.